#United States #New York #Securities Fraud #Rosen Law Firm #Park Ha Biotechnology

Legal Action Alert for Park Ha Biological Technology Investors

In a significant development for stakeholders of Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH), a global investor rights law firm, the Rosen Law Firm, has announced an urgent opportunity for shareholders to take part in a class action lawsuit. This legal action is specifically tailored for those who purchased securities between December 27, 2024, and July 8, 2025, during what is referred to as the "Class Period". The lawsuit has arisen due to numerous grievances concerning misleading statements and undisclosed facts regarding the company's operations, which adversely impacted the stock value and investor trust.

Why Investors Should Pay Attention

The deadline for investors seeking to be recognized as lead plaintiffs is approaching quickly, with a cut-off date set for September 28, 2026. Investors who incurred losses exceeding $100,000 during the Class Period may be eligible to recover their investments without incurring upfront costs, thanks to a favorable contingency fee arrangement provided by the Rosen Law Firm.

By taking part in the class action, investors can assert their rights and possibly secure compensation for their losses. The firm urges those affected to act promptly, as joining the lawsuit could be crucial in recovering losses suffered due to alleged fraudulent activities carried out by the defendants.

How to Join the Class Action

Interested investors are encouraged to visit the official Rosen Law Firm website at www.rosenlegal.com or directly connect with Phillip Kim, Esq. via email at [email protected] or toll-free at 866-767-3653. Joining the lawsuit not only allows individual stakeholders to seek potential restitution but also contributes to holding the corporation accountable for actions that might compromise investor integrity.

Understanding the Allegations

According to the details provided in the lawsuit, defendants representing Park Ha allegedly made false representations and omitted critical facts that could significantly influence an investor's decision. Specifically, the lawsuit indicates that the company was entwined in a fraudulent stock promotion scheme that involved misinformation on social media and deception from individuals posing as financial professionals.

Furthermore, during the Class Period, key disclosures were notably absent, such as the fraudulent rumors and artificial trading activities that were reportedly inflating stock prices unjustly. The IPO of Park Ha was purportedly structured with an unnaturally low public float, facilitating manipulation by interested parties. These flaws in communication have led to significant disillusionment among investors who trusted the publicly available information regarding Park Ha's operations and its future prospects.

The Rosen Law Firm's Proven Track Record

The Rosen Law Firm has a distinguished history advocating for investors with over a billion dollars recovered in settlement. Their commitment to guiding clients through the complex landscape of securities class actions emphasizes their depth of expertise and successful results, having been ranked first by ISS Securities Class Action Services in 2017 for their contributions to successful settlements against Chinese companies. Their founding partner, Laurence Rosen, has been recognized as a leader by multiple legal institutions, emphasizing the firm’s role as a formidable advocate for investor rights.

Important Considerations Before Taking Action

While the class action offers an avenue for potential recovery, it is essential to note that a class has not yet been certified. Until such a certification occurs, investors seeking representation can independently choose counsel. Participants are advised to remain vigilant and informed about their legal rights as stakeholders.

For continuing updates regarding the case and future developments, investors can engage with the Rosen Law Firm on social media platforms such as LinkedIn, Twitter, and Facebook.

In conclusion, if you are among the investors impacted by the actions (or inactions) of Park Ha Biological Technology, now is the time to act. Your involvement in the upcoming class action could be essential for your recovery efforts and holds the potential for altering the trajectory of investor-trust in the biotech sector.